NICE publishes new guideline to better tackle TB
13 January 2016 | By Victoria White
The new guidance combines clinical advice and public health guidance for the first time...
List view / Grid view
News
GSK initiates Phase 1 study of IONIS-HBV-LRx; Ionis gets milestone payment
13 January 2016 | By Victoria White
IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus...
Glioblastoma treatment market to increase to $3.3 billion
13 January 2016 | By Victoria White
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, according to research and consulting firm GlobalData...
One-hour diagnosis of heart attack possible with Roche’s troponin T test
13 January 2016 | By Victoria White
Results from a study demonstrate that Roche’s cardiac troponin T-high-sensitivity test shortens the time to diagnose heart attack to one hour from three hours or more...
Sjögren’s syndrome treatment market to grow to $2.2b by 2024
13 January 2016 | By Victoria White
GlobalData states that this impressive growth will be driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021...
Dolomite aids drug encapsulation studies
12 January 2016 | By Dolomite
A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies...
MIURA GO-xHT most powerful clean-up system for dioxins and PCBs
12 January 2016 | By Shimadzu
Less solvent consumption, no cross contamination / Can be combined with Shimadzu’s GCMS-TQ8040 triple quadrupole / Both fulfill new EU 589/2014 regulation on analyzing dioxins and PCBs samples...
FDA grants Priority Review for venetoclax NDA
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
Rapidly develop drugs targeting Interleukins with new PathHunter® cell-based assays from DiscoveRx
DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announces the expansion of its PathHunter® cell-based assays portfolio with the release of PathHunter Interleukin cell-based assays.
Cytori launches managed access programme for ECCS-50 for scleroderma
12 January 2016 | By Victoria White
ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure...
Parkinson’s disease treatment pipeline holds significant potential, says GBI Research
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
Nestlé Health Science and Seres collaborate on Ecobiotics
12 January 2016 | By Victoria White
Nestlé Health Science has signed an exclusive agreement outside the US and Canada for Seres Therapeutics’ Ecobiotics in clostridium difficile infections and inflammatory bowel disease...
Eisai submits MAA for lenvatinib in renal cell carcinoma
12 January 2016 | By Victoria White
Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy...
Tiziana announces development plans for foralumab
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
Shire to acquire Baxalta in $32 billion deal
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
